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Abstract
Background: Androgen-deprivation therapy (ADT) is standard treatment for locally advanced or
metastatic prostate cancer (PCa). Many patients develop castration resistance (castration-resistant
PCa [CRPC]) after approximately 2–3 yr, with a poor prognosis. The molecular mechanisms
underlying CRPC progression are unclear.
Objective: To undertake quantitative tumour transcriptome proﬁling prior to and following ADT to
identify functionally important androgen-regulated pathways or genes that may be reactivated in
CRPC.
Design, setting, and participants: RNA sequencing (RNA-seq) was performed on tumour-rich,
targeted prostatic biopsies from seven patients with locally advanced or metastatic PCa before
and approximately 22 wk after ADT initiation. Differentially regulated genes were identiﬁed in
treatment pairs and further investigated by quantitative reverse transcription-polymerase chain
reaction (qRT-PCR) on cell lines and immunohistochemistry on a separate CRPC patient cohort.
Functional assays were used to determine the effect of pathway modulation on cell phenotypes.
Outcome measurements and statistical analysis: We searched for gene expression changes affect-
ing key cell signalling pathways that may be targeted as proof of principle in a CRPC in vitro cell line
model.
Results and limitations: We identiﬁed ADT-regulated signalling pathways, including the Wnt/b-
catenin signalling pathway, and observed overexpression of b-catenin in a subset of CRPC by
immunohistochemistry. We validated 6 of 12 (50%) pathway members by qRT-PCR on LNCaP/
LNCaP-AI cell RNAs, of which 4 (67%) demonstrated expression changes consistent with RNA-seq
data. We show that the tankyrase inhibitor XAV939 (which promotes b-catenin degradation)
reduced androgen-independent LNCaP-AI cell line growth compared with androgen-responsive
LNCaP cells via an accumulation of cell proportions in the G0/G1 phase and reduction in the S and
G2/M phases. Our biopsy protocol did not account for tumour heterogeneity, and pathway
inhibition was limited to pharmacologic approaches.
Conclusions: RNA-seq of paired PCa samples revealed ADT-regulated signalling pathways. Proof-
of
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At diagnosis,manymenhave ‘‘incurable’’ locally advanced or
metastatic prostate cancer (PCa), themost commoncancer in
Europe [1]. PCa progression is initially driven by androgens
acting via the cognate androgen receptor (AR) transcription
factor. The initial treatment standard for patientswith locally
advanced ormetastatic PCa is androgen-deprivation therapy
(ADT), which inactivates the AR for a period of time. After
approximately 2–3 yr, these patients can develop castration-
resistant PCa (CRPC), for which the prognosis is poor despite
newer second-line cytotoxic chemotherapy and endocrine
therapies [2–4]. There is an urgent, unmet need for novel
therapies for CRPC led by a better understanding of the
biology underlying treatment resistance.
The mechanisms underlying CRPC are unclear and may
be the result of cellular adaptation to or clonal selection
by ADT [5]. AR signalling pathways and transcriptional
activity may be reactivated [6], or cell growth may be
supported by AR-independent outlaw cell signalling path-
ways [7]. Hence, a greater understanding of ADT-driven
molecular changes may yield information on the mecha-
nisms underlying progression to CRPC. Although previously
published transcriptome-wide studies have successfully
identified ADT-driven transcriptional events [8,9], these
analyses have been limited by the inherent bias associated
with microarrays [10].
In this study, we undertake quantitative transcriptome
profiling of prostate tumours from patients prior to and
following ADT using next-generation sequencing (RNA-seq)
to identify functionally important novel androgen-
regulated pathways and specific gene products that may
be reactivated in CRPC as potential targets for therapy.
2. Materials and methods
2.1. Patient samples for RNA sequencing
Clinical samples for RNA-seq were prospectively collected as part of the
GenTax study [11]. IlluminaRNA-seqwasperformedwithcomplementary
DNA sample library normalisation using the Illumina duplex-speciﬁcTable 1 – Patient demographics
Patient Age, yr KPS GSS TNM stage
T N
1 64.7 100 8 3b 0
2 65.4 90 9 3b 0
3 69.6 100 8 3b 1
4 64.6 90 8 3a 0
5 51.8 90 7 3a 0
6 58.6 100 7 3b 1
7 62.9 90 7 3b 1
8* 54.9 90 7 3a 2
KPS = Karnofsky performance status; GSS = Gleason sum score; iPSA = initial prost
value; PFS = progression-free survival; N/P = not yet progressed to date; RNA-Seq
ultrasound.
* Patient excluded from RNA-seq analysis. All patients exhibited a response to AD
The mean time to second TRUS biopsy was 202  143 d, and the mean time to bionucleaseprotocol prior to cluster generationand library sequencingon the
HiSeq 2000 sequencer (Illumina, San Diego, CA, USA) with a paired-end
sequencing strategy. Further details are given in the Supplement.
2.2. Functional assays
All cells were grown at 37 8C in 5% carbon dioxide. LNCaP (CRL-1740,
ATCC) cells were maintained in RPMI-1640 medium (Life Technologies,
Carlsbad, CA, USA; 31870-025) with 20 mM L-glutamine (Life Technol-
ogies, 25030-024) supplemented with 10% foetal bovine serum (PAA
Laboratories, Yeovil Somerset, UK; A15-101). LNCaP-AI cells were
derived from LNCaP parental cells and maintained as previously
described [12]. Proliferation assays were carried out using the WST-1
reagent (Roche Diagnostics, Indianapolis, IN, USA; 05015944001) as per
the manufacturer’s instructions in medium containing either 10 mm
XAV939 (Novartis Pharmaceuticals, Plantation, FL, USA) in 0.1% dimethyl
sulfoxide (DMSO) [13] or vehicle. Cell cycle analysis was performed
following treatment with 10 mm XAV939 in 0.1% DMSO or vehicle, as
previously described [14]. Further details are given in the Supplement.
3. Results
3.1. The transcriptional landscape of androgen-deprivation
therapy in clinical prostate cancer
RNA-seq was performed on 16 paired pre- and post-ADT
samples from eight patients with locally advanced or
metastatic PCa (Gleason score >7 [15]; Table 1). The post-
ADT sample from patient 8 performed markedly worse on
multiple quality control measures, and so both samples
from this patient were excluded from further analysis
(Supplemental Table 1). Recently, genomic rearrangements
rendering ETS-family transcription factors under the control
of androgen-responsive or other promoters have been
hypothesised as a mechanism driving prostate carcinogene-
sis [16]. The TMPRSS2/ERG translocation yields the most
common PCa-associated gene fusion product, reported in
>50% cases [16]. Consistent with this, three of the seven
(43%) patients expressed transcripts with sequences corre-
sponding to this fusion event in the pre-ADT samples alone.
We observed, on average, a sixfold downregulation of ERG
expression following ADT, but expression of TMPRSS2/ERGiPSA, ng/ml nPSA, ng/ml (% iPSA) PFS, d
M
0 370 3.1 (0.8) 942
0 7.6 0.7 (0.1) 155
0 5.9 0.7 (0.1) 223
1 47.7 0.5 (1.6) N/P
0 158 0.4 (0.3) N/P
0 69 0.13 (0.2) 489
0 32.7 <0.02 (0.06) N/P
1 7.4 0.06 (0.8) 154
ate-speciﬁc antigen value at diagnosis; nPSA = nadir prostate-speciﬁc antigen
= RNA sequencing; ADT = androgen-deprivation therapy; TRUS = transrectal
T prior to second TRUS biopsy, as determined by a fall in levels of serum PSA.
chemical or radiologic progression was 392  336 d.
Table 2 – Differentially expressed genes following androgen-
deprivation therapy
Gene set Up Down
Protein coding 774 755
Noncoding 35 116
Numbers of protein coding and noncoding genes differentially expressed
at least twofold after androgen-deprivation therapy, with a false discovery
rate <0.05.
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 3 2 – 3 934did not correlate with time to biochemical relapse (data not
shown). We also identified 12 additional candidate fusion
products, 9 of which were only detectable in pre-ADT
samples (Supplemental Table 2).
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FDR = false discovery rate; PSA = prostate-specific antigen.We identified a total of 774 genes upregulated at least
twofold (false discovery rate [FDR]<0.05) in response toADT
and 755 genes similarly downregulated (Table 2 and
Supplemental Table 3). Examples of genes differentially
regulated andunchangedbyADTare shown in Supplemental
Figure 1A. Levels of expression of KLK3, which encodes
prostate-specific antigen (PSA), detected by RNA-seq corre-
lated well with serum PSA levels for all but one patient
(Fig. 1A). Comparing against data from two previously
published microarray-based gene expression analyses prior
to and following ADT [8,9], we confirmed approximately 42%
of the genes each of these previous studies had found and
additionally identified a large number of previously un-
known ADT-regulated genes (Fig. 1B).This study
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might directly result from changes in AR activity, we used a
list of geneswhose regulatory regionswere bound by the AR
from published chromatin immunoprecipitation sequenc-
ing data on patient tissue [17]. Seven (1.7%) of the 331 genes
with AR binding peaks [17] within 2 kb of the transcription
start site were significantly upregulated in expression
twofold, but 35 (8.8%) were significantly downregulated
twofold, which is greater than twice as many as would be
expected by chance ( p < 1  105). In line with previous
reports, we conclude that direct AR binding is a significant
but minor determinant of overall expression changes.
Nevertheless, we do note that most AR binding events
occur outside promoters, presumably within enhancers.
To identifybiologicpathwaysperturbed followingADT, an
enrichment analysis was performed on our lists of up- and
downregulated genes (FDR <0.05) using the Kyoto Encyclo-
paedia of Genes and Genomes (KEGG) database [18]. We
identified 24 pathways significantly enriched for the
upregulated genes (enrichment more than twofold; FDR
<0.05) and 19 enriched for the downregulated genes
(Supplemental Table 4 and Fig. 1). To understand themes
associated with enriched pathways, we clustered pathways
by the fractionofdifferentially regulatedgenes sharedby two
pathways (Fig. 1C and Supplemental Fig. 1B). For pathways
enriched for upregulated genes, three clusters became
apparent, including a cluster containing cancer-related[(Fig._2)TD$FIG]
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Fig. 2 – Differential expression of genes encoding components of the Wnt/b-ca
base 2) after androgen-deprivation therapy of genes in both up- and downregu
Genes and Genomes term Wnt signalling pathway.pathways, such as Prostate cancer, Pathways in cancer, and
Wnt signalling pathway (Fig. 1C). Pathways enriched for
downregulated genes consisted mostly of metabolic path-
ways (Supplemental Fig. 1B).
In light of evidence implicating cross-talk of AR signalling
with other pathways (eg, PI3K/Akt/mTOR) in PCa [19], we
focused on KEGG terms relating to cell signalling pathways.
With the exception of the general Pathways in cancer, the
KEGG term Wnt signalling pathway contained the largest
number of significantly upregulated genes (Supplemental
Table 4 and Fig. 2; 29 of 150; enrichment was twofold; FDR
<0.05) among the cluster of upregulated cancer pathways.
The Wnt/b-catenin signalling pathway is a proproliferative
pathway inPCa [20], and enrichment for thispathwaywas an
unexpected finding in the upregulated gene set. Fourteen of
the upregulated genes were also found to be upregulated in
one or other of the previously published studies on ADT-
driven gene expression changes (34 patients) [8,9].
Taken together, thesedata suggest that theWnt/b-catenin
signalling pathway is regulated, either directly or indirectly,
by androgens in vivo. Specific components of the Wnt/b-
catenin signalling pathway have been implicated in AR
signalling in vitro [21] and with ADT in clinical PCa [22] as
well as inmurine prostate development and PCa progression
[23]. Recent exome-sequencing studies have identified
mutations in genes encoding components of the pathway
in PCa [24,25], but its role in clinical CRPC remains unclear.AMK2D CCND2 CHP1 CHP2
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lated gene sets, annotated as being part of the Kyoto Encyclopaedia of
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Fig. 3 – Inhibition of the Wnt/b-catenin signalling pathway limits growth and delays cell cycle progression of LNCaP-AI cells. (A) WST-1 proliferation assays
were performed using either LNCaP cells grown in full medium or LNCaP-AI cells grown in DCC. Cells were treated with 10 mm XAV939 in 0.1% dimethyl
sulfoxide (DMSO) or vehicle. Values were normalised to the growth of LNCaP cells in full medium without any treatment. Data from at least three
independent experiments were used to obtain the mean relative growth plus or minus standard deviation (SD) for each cell type and treatment condition.
(B) Cell cycle analysis was performed using either LNCaP cells grown in full medium or LNCaP-AI cells grown in DCC. Cells were treated with 10 mm
XAV939 in 0.1% DMSO or vehicle. Plots shown are representative of at least three independent experiments, from which (C) percentages of cells in each
phase of the cell cycle were calculated for each cell type and treatment condition to obtain mean percentage plus or minus SD.
BrdU = BrdU fluorescence intensity.
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contributes to CRPC, we used immunohistochemistry to
investigate b-catenin protein expression in a panel of
36 matched pairs of hormone-naı¨ve PCa (HNPC) and
CRPC. Among the 29 informative tumour pairs, 16 pairs
demonstrated b-catenin overexpression in CRPC samples
(Supplemental Fig. 2). In addition, a statistically significant
correlation exists between b-catenin and nuclear AR protein
expression in CRPC (r = 0.440; p = 0.017) but not HNPC
(r = 0.15; p = 0.375). These data are consistent with the
notion that b-catenin is involved in PCa progression in a
cohort of tumours and may be associated with AR reactiva-
tion in CRPC.
3.2. Inhibition of the Wnt/b-catenin signalling pathway limits
androgen-independent prostate cancer cell growth via a delay in
cell cycle progression
We next investigated whether perturbations within the
Wnt/b-catenin signalling pathway may be functionally
important in CRPC. To verify the RNA-seq data, we took
advantage of two in vitro models: the LNCaP PCa cell line as
a model for HNPC and the LNCaP-AI subline, derived from
continued culture of LNCaP cells in steroid-deplete medium
(DCC), as a model for CRPC. To check the validity of these
models, we searched for significantly downregulated genes
within the KEGG term Wnt signalling pathway in a
previously published exon-level analysis of the androgen-
responsive LNCaP transcriptome [26]. We observed andro-
gen-dependent downregulation of expression of 35 path-
way genes (FDR <0.05), of which 7 were significantly
upregulated in the RNA-seq data set, suggesting that LNCaP
cells may be suitable for modelling our in vivo findings.
Twelve candidate canonical Wnt/b-catenin signalling
pathway components differentially expressed between pre-
and post-ADT samples in the initial RNA-seq analysis were
further investigated by quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) analysis on RNAs
extracted from LNCaP and LNCaP-AI cells (Supplemental
Table 5). Of the 12 candidates, expression of 6 (50%) genes
could be detected by qRT-PCR in these cell lines, which may
be the result of cell line–specific gene expression. Of the six
validated candidates, four (67%) demonstrated expression
changes consistent with RNA-seq data. These included the
signal-transducing Frizzled family serpentine receptors
(FZD4/FZD5/FZD7) and the pathway downstream effector
JUN.
Extracellular Wnt signals are transduced by two
receptors, a Frizzled family member and a transmembrane
protein LRP5 or LRP6, which together form a complex
following binding by cysteine-rich Wnt proteins. The Frz-
LRP5/6 complex then inactivates the b-catenin degradation
complex (which includes axin and GSK3b), thus allowing b-
catenin nuclear translocation [20]. As a proof-of-principle
experiment, we tested the functional effects of the Wnt/b-
catenin signalling in CRPC using LNCaP-AI cells [27] by
WST-1 proliferation assays in the presence of a well-
characterised Wnt/b-catenin signalling inhibitor [13]
(Fig. 3A). We treated LNCaP or LNCaP-AI cells (grown infull medium or DCC, respectively) with 10 mm XAV939, an
inhibitor of tankyrase 1 and 2 (which stabilise axin and
promote b-catenin degradation) [13], or vehicle. Compared
with controls, treatment with XAV939 reduced growth of
LNCaP cells in full medium by approximately 30% and had
even stronger effects on LNCaP-AI cells, potently diminish-
ing cell growth by approximately 75% (p < 0.05; Fig. 3A).
To determine whether the above reduction in cell
proliferation reflected a delay in cell cycle progression,
LNCaP or LNCaP AI cells treated with 10 mm XAV939 or
vehiclewere subjected to cell cycle analysis (Fig. 3B and 3C).
In the absence of treatment, synchronised LNCaP cells were
predominantly in the G0/G1 phase, with a smaller propor-
tion of cells in the S or G2/M phase. Compared with LNCaP
cells, a larger proportion of synchronised LNCaP-AI cells
were in the G0/G1 phase, with a smaller proportion in the S
or G2/M-phase, demonstrating that the cell cycle of LNCaP-
AI cells progresses more slowly than the parental cell line,
as previously described [28]. Following treatment with
XAV939, there was no statistically significant difference in
the proportion of LNCaP cells in the G0/G1 phase compared
with control ( p > 0.05) and only small (approximately 3–
5%) differences in the proportion of cells in the S and G2/M
phases. However, there was a 17% increase in the
proportion of LNCaP-AI cells in the G0/G1 phase
( p < 0.05) and a 10% fall in the proportion of cells in the
S phase ( p < 0.05). These data suggest that, in LNCaP-AI
cells, XAV939 treatment specifically causes an accumula-
tion of cells in the G0/1 phase and a reduction of cells in the
S andG2/Mphases, thereby delaying cell cycle progression.
Taken together, these data suggest that the LNCaP-AI
subline is particularly dependent on the Wnt/b-catenin
signalling pathway for cell growth.
4. Discussion
We report the first quantitative transcriptome profiling of
clinical PCa from patients prior to and following ADT by
using RNA-seq and have substantially enlarged the ADT-
regulated gene set, as is expected from a more sensitive
sequencing study [29–31]. The substantially better overlap
between our and the two previously published microarray
gene sets [8,9] contrasts with the poor individual overlap of
the gene sets between these two studies, which may be the
result of a lack of power of these studies to identify
differentially regulated genes. Specifically, we identified
several novel pathways perturbed by ADT, including the
Wnt/b-catenin signalling pathway. Although activation of
Wnt/b-catenin signalling in carcinogenesis is well known
in breast and colorectal cancers [32], evidence for this
pathway in clinical PCa has been conflicting. Recent exome-
sequencing studies have identified mutations with genes
encoding components of the Wnt/b-catenin signalling
pathway [24,25], but there is no clear consensus on the
significance of increased nuclear b-catenin expression in
primary PCa based on immunohistochemistry [20].
The current focus of novel therapies for CRPC is the
targeting of renewed AR signalling [2,3,19]. In CRPC, an
inverse correlation has been observed between b-catenin
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 3 2 – 3 938nuclear localisation and AR expression [33], yet others
report no statistically significant difference in expression
following progression from hormone-naı¨ve disease to CRPC
[34]. We demonstrate overexpression of b-catenin in a
subset of CRPC and correlation with expression of AR
consistent with AR reactivation. Functional or physical
interactions between AR andWnt/b-catenin signalling have
been reported in vitro, with b-catenin functioning as an AR
coactivator [20,32] to drive ligand-independent cell growth.
Despite conflicting results from immunohistochemistry
experiments in clinical PCa, which may be caused by
experimental variability [34], the above reports together
with our own observations suggest that Wnt/b-catenin
signalling may be active in CRPC. In keeping with this
hypothesis, expression of putative inhibitors of Wnt/b-
catenin signalling and downstream transcription factors
were downregulated following progression to CRPC in an
LNCaP xenograft model [35]. It is thought that these
expression changes may lead to an increase cytoplasmic
pool of b-catenin, allowing potential interaction with
unliganded AR and other transcription factors.
We observed a potent inhibitory effect of XAV939
treatment on LNCaP-AI cell growth, which appeared to be
caused by an accumulation of cells in the G0/1 phase of the
cell cycle (Fig. 3), suggesting a functional role for Wnt/b-
catenin signalling in CRPC. The molecular mechanisms
underlying our observations remain unclear, and an
exhaustive investigation thereof was outside the scope of
this proof-of-principle study. Despite using awell-validated
inhibitor of Wnt/b-catenin signalling, a potential limitation
of this approach is off-target effects.
We identified ADT-driven changes in components of cell
signalling pathways, including the Wnt/b-catenin signal-
ling pathway, approximately 22 wk following ADT initia-
tion. Although our patients had not yet developed CRPC at
the time of the second biopsy, some did develop early
biochemical relapse. A caveat of our approach is the
targeted biopsy regime, which, although it yields tumour-
rich tissue, could have included a heterogeneous population
of epithelial and stromal cells. However, a surprising
observation was that our KEGG analysis identified upregu-
lation of expression of cancer gene–related pathways,
which would have been expected to be downregulated if
stromal expression signatures were overtly expressed.
5. Conclusions
Our observations suggest that CRPC may represent repopu-
lation of a tumour with androgen-independent clones
reliant on Wnt/b-catenin signalling activity after sustained
ADT. In light of recent data suggesting that Wnt ligand
expression by the tumour microenvironment may attenu-
ate cytotoxic chemotherapy and confer treatment resis-
tance [36], Wnt/b-catenin signalling may represent a
potential target for therapy in PCa. Further mechanistic
insights using genetic approaches such as in vitro RNA
interference and genetically engineered autochthonous
murine cancer models will determine whether this
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